RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Krystal Biotech Stock

Krystal Biotech EBIT 2024

Krystal Biotech EBIT

57.94 M USD

Ticker

KRYS

ISIN

US5011471027

WKN

A2JH2F

In 2024, Krystal Biotech's EBIT was 57.94 M USD, a -159.59% increase from the -97.23 M USD EBIT recorded in the previous year.

The Krystal Biotech EBIT history

YEAREBIT (undefined USD)
2029e-
2028e549.17
2027e434.36
2026e300.04
2025e173.49
2024e57.94
2023-97.23
2022-120.2
2021-68.28
2020-33
2019-22.08
2018-11.92
2017-4.77
2016-1.14

Krystal Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Krystal Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Krystal Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Krystal Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Krystal Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Krystal Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Krystal Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Krystal Biotech’s growth potential.

Krystal Biotech Revenue, EBIT and net profit per share

DateKrystal Biotech RevenueKrystal Biotech EBITKrystal Biotech Net Income
2029e1.1 B undefined0 undefined371.58 M undefined
2028e953.6 M undefined549.17 M undefined424.04 M undefined
2027e802.83 M undefined434.36 M undefined332.24 M undefined
2026e668.58 M undefined300.04 M undefined265.79 M undefined
2025e502.06 M undefined173.49 M undefined173.26 M undefined
2024e299.62 M undefined57.94 M undefined75.93 M undefined
202350.7 M undefined-97.23 M undefined10.93 M undefined
20220 undefined-120.2 M undefined-139.98 M undefined
20210 undefined-68.28 M undefined-69.57 M undefined
20200 undefined-33 M undefined-32.17 M undefined
20190 undefined-22.08 M undefined-19.09 M undefined
20180 undefined-11.92 M undefined-10.89 M undefined
20170 undefined-4.77 M undefined-7.92 M undefined
20160 undefined-1.14 M undefined-1.15 M undefined

Krystal Biotech stock margins

The Krystal Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Krystal Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Krystal Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Krystal Biotech's sales revenue. A higher gross margin percentage indicates that the Krystal Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Krystal Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Krystal Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Krystal Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Krystal Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Krystal Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Krystal Biotech Margin History

Krystal Biotech Gross marginKrystal Biotech Profit marginKrystal Biotech EBIT marginKrystal Biotech Profit margin
2029e93.9 %0 %33.66 %
2028e93.9 %57.59 %44.47 %
2027e93.9 %54.1 %41.38 %
2026e93.9 %44.88 %39.75 %
2025e93.9 %34.56 %34.51 %
2024e93.9 %19.34 %25.34 %
202393.9 %-191.77 %21.56 %
202293.9 %0 %0 %
202193.9 %0 %0 %
202093.9 %0 %0 %
201993.9 %0 %0 %
201893.9 %0 %0 %
201793.9 %0 %0 %
201693.9 %0 %0 %

Krystal Biotech Aktienanalyse

What does Krystal Biotech do?

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Krystal Biotech's EBIT

Krystal Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Krystal Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Krystal Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Krystal Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Krystal Biotech stock

How much did Krystal Biotech achieve in EBIT for the current year?

In the current year, Krystal Biotech has achieved an EBIT of 57.94 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Krystal Biotech.

How has the EBIT of Krystal Biotech developed in recent years?

The EBIT of Krystal Biotech has increased by -159.59% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Krystal Biotech?

The EBIT of Krystal Biotech is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Krystal Biotech pay?

Over the past 12 months, Krystal Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Krystal Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Krystal Biotech?

The current dividend yield of Krystal Biotech is .

When does Krystal Biotech pay dividends?

Krystal Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Krystal Biotech?

Krystal Biotech paid dividends every year for the past 0 years.

What is the dividend of Krystal Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Krystal Biotech located?

Krystal Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Krystal Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Krystal Biotech from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Krystal Biotech pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Krystal Biotech in the year 2023?

In the year 2023, Krystal Biotech distributed 0 USD as dividends.

In which currency does Krystal Biotech pay out the dividend?

The dividends of Krystal Biotech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Krystal Biotech

Our stock analysis for Krystal Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Krystal Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.